United Therapeutics (NASDAQ:UTHR) Stock: Insider Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Monday, October 19th. The stock was sold at an average price of $543.32, for a total value of $5,161,540.00. Following the transaction, the chief executive officer owned 324,443 shares of the company’s stock, valued at $176,276,370.76. The trade was a 2.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

United Therapeutics Stock Up 1.7%

Shares of NASDAQ UTHR opened at $563.49 on Thursday. The business’s 50 day moving average price is $515.71 and its two-hundred day moving average price is $539.59. The company has a market cap of $24.17 billion, a PE ratio of 20.16, a price-to-earnings-growth ratio of 3.96 and a beta of 0.49. United Therapeutics Corporation has a twelve month low of $409.07 and a twelve month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. The company had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The business’s revenue was down 1.9% on a year-over-year basis. During the same period last year, the firm posted $6.41 earnings per share. As a group, research analysts anticipate that United Therapeutics Corporation will post 26.40 EPS for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds have recently added to or reduced their stakes in UTHR. Cardinal Capital Management grew its holdings in shares of United Therapeutics by 0.5% during the 3rd quarter. Cardinal Capital Management now owns 12,033 shares of the biotechnology company’s stock worth $6,521,000 after purchasing an additional 63 shares in the last quarter. PFS Partners LLC acquired a new position in United Therapeutics in the third quarter valued at about $45,000. Crossmark Global Holdings Inc. raised its stake in United Therapeutics by 7.8% in the third quarter. Crossmark Global Holdings Inc. now owns 3,189 shares of the biotechnology company’s stock valued at $1,728,000 after purchasing an additional 232 shares in the last quarter. Quadrant Capital Group LLC raised its stake in United Therapeutics by 1.1% in the third quarter. Quadrant Capital Group LLC now owns 5,013 shares of the biotechnology company’s stock valued at $2,724,000 after purchasing an additional 54 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. lifted its position in United Therapeutics by 18.8% during the third quarter. Robeco Institutional Asset Management B.V. now owns 146,163 shares of the biotechnology company’s stock worth $79,204,000 after purchasing an additional 23,107 shares during the period. Institutional investors own 94.08% of the company’s stock.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Analysts raised their outlook. Leerink Partners increased its price target for United Therapeutics to $725 from $685 while maintaining an “outperform” rating. The broader analyst consensus remains bullish, with a “Moderate Buy” rating and an average target near $650, implying further potential upside. Leerink Partners Raises Price Target
• Positive Sentiment: United Therapeutics expanded its xenograft capacity. The company opened its third designated pathogen-free xenograft production facility in Houston, Texas. The facility supports its longer-term strategy of developing genetically modified organs for transplantation and may strengthen future growth opportunities beyond its pulmonary hypertension drug franchise. Third Xenograft Production Facility
• Neutral Sentiment: Third-quarter earnings are approaching. United Therapeutics will report financial results before the market opens on November 4. The release could provide an important update on demand for Tyvaso and other pulmonary hypertension treatments, margins, and progress in organ manufacturing. Third-Quarter 2026 Earnings Announcement
• Negative Sentiment: Insider selling presents a modest cautionary signal. CEO Martine Rothblatt reported sales of 9,500 shares in transactions dated October 16 and October 19, reducing her position by about 2.84% in each filing. The company’s general counsel also sold shares under a trading plan. Because the sales appear relatively small compared with Rothblatt’s remaining stake and were conducted under planned arrangements, they do not necessarily indicate deteriorating business prospects.

Analyst Ratings Changes

Several analysts recently issued reports on UTHR shares. Raymond James Financial restated an “outperform” rating and issued a $717.00 price target on shares of United Therapeutics in a research note on Tuesday. Morgan Stanley increased their price objective on United Therapeutics from $515.00 to $566.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 7th. Bank of America dropped their target price on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of United Therapeutics in a report on Thursday, October 1st. Finally, JPMorgan Chase & Co. boosted their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Twelve analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $651.21.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.